Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02673606 · ClinicalTrials.gov registry record · Phase 1
Impact of Estrogen on Fear Extinction R61
A Phase 1 study of Fear and Fear; Examination, Phobic, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT02673606: Completed Phase 1 study of Fear and Fear; Examination, Phobic, sponsored by NYU Langone Health.
NCT02673606 is a Phase 1 study of Fear and Fear; Examination, Phobic that has completed, run by NYU Langone Health. The registered enrollment target is 136 participants, below the 251-participant average among 8 other Fear trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02673606, a Phase 1 study of Fear and Fear; Examination, Phobic, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this project is to examine how estrogen may influence the resting-state connectivity and the extinction-induced activation of the fear extinction network.
Primary Outcome
BOLD responses during fear extinction after taking estradiol or placebo
Conditions Studied
Interventions
- DRUG Estradiol 2Mg Tablet
- DRUG Estradiol 4Mg Tablet
- DRUG Placebo Pills
Study Locations (1)
New York
- NYU School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2013-01 |
| Est. Completion | 2019-04-15 |
| Phase | Phase 1 |
What the finished NCT02673606 record still lists
NCT02673606 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 251-participant average among 8 other Fear trials with a reported enrollment target (46% lower).
The record links to 2 conditions, with Fear appearing as the primary indexed condition, and to 3 interventions - of which Estradiol 2Mg Tablet is the first listed.
NCT02673606 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02673606 about?
NCT02673606 is a clinical study titled "Impact of Estrogen on Fear Extinction R61". The goal of this project is to examine how estrogen may influence the resting-state connectivity and the extinction-induced activation of the fear extinction network.
What is the current status of trial NCT02673606?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2013-01. Estimated completion is 2019-04-15.
What conditions does trial NCT02673606 study?
This clinical trial studies the following conditions: Fear, Fear; Examination, Phobic.
What interventions are being tested in trial NCT02673606?
The interventions under investigation include: Estradiol 2Mg Tablet (DRUG), Estradiol 4Mg Tablet (DRUG), Placebo Pills (DRUG).
Who is sponsoring clinical trial NCT02673606?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02673606 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fear
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02673606's enrollment target sits among peer trials
136 4th of 8 higher than 5 of 8 other Fear trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fear trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Social Support and Reduced Fear Acquisition
RECRUITING · NA
-
Social Support and Enhanced Fear Extinction
RECRUITING · NA
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans
RECRUITING · NA
-
Addressing Anxiety in 2-3-Year-Olds: A Pilot Intervention Study
ACTIVE NOT RECRUITING · NA
-
Effect of rTMS on Anxiety
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia